~262 spots leftby Aug 2026

Elranatamab for Multiple Myeloma

Recruiting in Palo Alto (17 mi)
+152 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Recruiting
Sponsor: Pfizer
Must be taking: Anti-CD38, Lenalidomide
Must not be taking: BCMA therapy, CD3 therapy
Disqualifiers: Smoldering MM, Plasma cell leukemia, Amyloidosis, others
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab to other medicines for the treatment of MM (a type of cancer). This study is seeking participants who: * Are 18 years of age or older and have MM. * Have received treatments before for MM. * Have MM that has returned or not responded to their most recent treatment. Half of the participants will receive elranatamab. The other half of participants will receive a combination therapy selected by the study doctor. The selected combination therapy will include 2 to 3 different medicines commonly used to treat MM. Elranatamab will be given as a shot under the skin at the study clinic about once a week. This may change to a smaller number of shots later in the study. The medicines in the combination therapy will be taken by mouth (at home or at the study clinic) AND will be given either as: * a shot under the skin at the study clinic * through a needle in the vein at the study clinic The number of times these medicines will be taken depends on what combination therapy the study doctor selects. Participants may continue to receive elranatamab or a combination therapy until their MM is no longer responding. The study team will see how each participant is doing with the study treatment during regular visits at the study clinic. The study team will continue to follow-up with participants after study treatment with telephone contacts (or visits). The study will compare the experiences of people receiving elranatamab to those people receiving a combination therapy. This will help learn about the safety and how effective elranatamab is.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It is best to discuss this with the study doctor to understand how your current treatments might interact with the trial.

What data supports the effectiveness of the drug Elranatamab for treating multiple myeloma?

Elranatamab has shown promising results in clinical trials for multiple myeloma, with a significant number of patients responding to the treatment. In the MagnetisMM-1 trial, 63.6% of patients experienced a positive response, and the drug demonstrated durable responses and manageable safety, offering hope for those with relapsed or refractory multiple myeloma.12345

Is Elranatamab safe for humans?

Elranatamab has been tested in clinical trials for multiple myeloma, and no dose-limiting toxicities (serious side effects that prevent increasing the dose) were observed. Some side effects included low blood cell counts and cytokine release syndrome (a reaction that can cause fever and flu-like symptoms), but overall, the safety was considered manageable.12367

What makes the drug Elranatamab unique for treating multiple myeloma?

Elranatamab is unique because it is a bispecific antibody that targets both BCMA on myeloma cells and CD3 on T cells, activating the T cells to attack the cancer cells. It is administered subcutaneously and has shown promising results in patients who have already undergone multiple other treatments, offering a new option for those with relapsed or refractory multiple myeloma.12378

Research Team

PC

Pfizer CT.gov Call Center

Principal Investigator

Pfizer

Eligibility Criteria

This trial is for adults with Multiple Myeloma (MM) that has returned or hasn't responded after treatment, including anti-CD38 antibody and lenalidomide. Participants must have had 1 to 4 prior MM treatments, meet specific lab value criteria, not be pregnant or breastfeeding, and agree to use contraception.

Inclusion Criteria

You are not pregnant or breastfeeding and are okay with using birth control.
My last cancer treatment did not work according to IMWG standards.
My last cancer treatment did not work as expected.
See 9 more

Exclusion Criteria

I do not have any ongoing serious infections.
I haven't had any cancer except for certain skin cancers or localized cancers that were treated, in the last 3 years.
I cannot undergo the standard treatment recommended by my doctor.
See 9 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive elranatamab or a combination therapy until their MM is no longer responding

Up to approximately 5 years
Weekly visits initially, with potential reduction in frequency

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to approximately 35 days after last administration of study intervention
Telephone contacts or visits

Treatment Details

Interventions

  • Elranatamab (Monoclonal Antibodies)
Trial OverviewThe study compares elranatamab—a new medication given as a weekly shot—with a combination of standard MM therapies chosen by the doctor. The goal is to evaluate elranatamab's safety and effectiveness against these common treatments.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: ElranatamabExperimental Treatment1 Intervention
Participants will receive elranatamab monotherapy
Group II: Investigator's ChoiceActive Control5 Interventions
Participants will receive either Elotuzumab, Pomalidomide and Dexamethasone (EPd), or Pomalidomide, Bortezomib and Dexamethasone (PVd), or Carfilzomib and Dexamethasone (Kd)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Pfizer

Lead Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Findings from Research

Elranatamab is a bispecific T cell engager that targets BCMA on multiple myeloma cells, effectively activating T cells to kill these cancer cells, and has received its first approval in the USA for treating adult patients with relapsed or refractory multiple myeloma after at least four prior therapies.
The approval was based on the drug's response rate and durability of response, with ongoing studies required to confirm its clinical benefits, indicating a promising new option for patients with difficult-to-treat multiple myeloma.
Elranatamab: First Approval.Dhillon, S.[2023]
In the MagnetisMM-1 trial involving 88 patients with relapsed or refractory multiple myeloma, elranatamab demonstrated a significant overall response rate of 63.6%, with 38.2% of patients achieving a complete response or better, indicating its efficacy even in heavily pre-treated patients.
Elranatamab showed manageable safety with no dose-limiting toxicities during dose escalation, although some patients experienced cytopenias and cytokine release syndrome; the median progression-free survival was 11.8 months and overall survival was 21.2 months, suggesting promising durability of responses.
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.Bahlis, NJ., Costello, CL., Raje, NS., et al.[2023]
In a phase II study involving 15 patients with relapsed multiple myeloma, the combination of elotuzumab with carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) showed a 46.7% rate of achieving very good partial response (≥VGPR) after 4 cycles of treatment, indicating significant efficacy in a challenging patient population.
The treatment was well-tolerated with no new safety concerns reported, and the overall response rate was 80%, suggesting that Elo-KRd is a promising option for patients with high-risk and lenalidomide-refractory multiple myeloma.
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.Bhutani, M., Foureau, DM., Robinson, M., et al.[2023]

References

Elranatamab: First Approval. [2023]
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. [2023]
Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma. [2023]
A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse. [2023]
New investigational drugs with single-agent activity in multiple myeloma. [2022]
Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma. [2018]
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case. [2023]
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. [2023]